Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Incyte Corporation

    NASDAQ: INCY · Real-Time Price · USD
    71.13
    3.38 (4.99%)
    At close: Jun 16, 2025, 3:59 PM
    71.52
    0.55%
    After-hours: Jun 16, 2025, 07:05 PM EDT
    4.99%
    Bid 67.75
    Market Cap 13.77B
    Revenue (ttm) 4.41B
    Net Income (ttm) 21.27M
    EPS (ttm) 0.2
    PE Ratio (ttm) 355.65
    Forward PE 10.29
    Analyst Hold
    Ask 71.52
    Volume 2,665,202
    Avg. Volume (20D) 2,135,020
    Open 70.80
    Previous Close 67.75
    Day's Range 69.02 - 71.29
    52-Week Range 53.56 - 83.95
    Beta 0.68

    About INCY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol INCY
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for INCY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    23 hours ago
    Incyte shares are trading higher after the company... Unlock content with Pro Subscription
    1 month ago
    +1.53%
    INCY stock has given up its prior gain. Incyte shares were trading higher after the company reported better-than-expected Q1 financial results
    news image

    1 day ago · businesswire.com

    QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

    VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration t...

    news image

    1 day ago · businesswire.com

    Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

    WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025.

    news image

    4 days ago · businesswire.com

    Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

    WILMINGTON, Del.--(BUSINESS WIRE)--Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet.

    news image

    1 week ago · businesswire.com

    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

    news image

    1 week ago · businesswire.com

    Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

    WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2025--Multiple Incyte Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted at EHA 2025.

    news image

    2 weeks ago · zacks.com

    Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?

    Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

    news image

    2 weeks ago · businesswire.com

    Incyte to Present at Upcoming Investor Conference

    WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025 at 11:20 am (ET). The presentation will ...

    news image

    1 month ago · zacks.com

    Incyte Gets FDA Approval for Zynyz in New Cancer Indication

    The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.

    news image

    1 month ago · businesswire.com

    Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

    WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--FDA Approves Zynyz (retifanlimab-dlwr) the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States.

    news image

    1 month ago · seekingalpha.com

    Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript

    Incyte Corporation (NASDAQ:INCY ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Greg Shertzer - Director of Investor Relations Herve Hoppenot - Chief Executive Office...

    Add to Watchlist